Bank of New York Mellon
KLDO

Bank of New York Mellon’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Bank of New York Mellon’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-59,791
Closed -$99K – 4784
2022
Q1 		$99K Sell
59,791
-787
-1% -$1.4K ﹤0.01% 4406
2021
Q4 		$145K Sell
60,578
-18,736
-24% -$76.3K ﹤0.01% 4347
2021
Q3 		$433K Buy
79,314
+28,786
+57% +$179K ﹤0.01% 3888
2021
Q2 		$376K Buy
50,528
+5,069
+11% +$35.9K ﹤0.01% 3900
2021
Q1 		$368K Buy
45,459
+7,586
+20% +$82.6K ﹤0.01% 3835
2020
Q4 		$344K Buy
37,873
+6,156
+19% +$50.5K ﹤0.01% 3775
2020
Q3 		$351K Sell
31,717
-1,960
-6% -$13.6K ﹤0.01% 3652
2020
Q2 		$250K Sell
33,677
-1,042
-3% -$6.99K ﹤0.01% 3740
2020
Q1 		$214K Buy
34,719
+3,744
+12% +$24.4K ﹤0.01% 3726
2019
Q4 		$155K Buy
30,975
+13,729
+80% +$87.3K ﹤0.01% 3964
2019
Q3 		$130K Buy
+17,246
New +$150K ﹤0.01% 3984

Other funds holding KLDO

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bank of New York Mellon's KLDO Position: Q2 2022 in Review

Bank of New York Mellon sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 59,791 shares — an estimated $99K sold.

Bank of New York Mellon first reported a position in KLDO in Q3 2019 and held it in 11 quarters. The position peaked at $433K in Q3 2021. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

  • Bank of New York Mellon reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 59,791 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $99K.
  • Bank of New York Mellon first reported a position in Kaleido Biosciences, Inc. Common Stock in Q3 2019 and held it in 11 quarters.
  • Bank of New York Mellon's Kaleido Biosciences, Inc. Common Stock position peaked at $433K in Q3 2021.
  • 3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.